Sunil Sharma, MD, FACP, MBA

Research Interests

  • Clinical Trials, Phase I
  • Gastrointestinal Cancers
  • Targeted Drug Delivery Systems
  • Small Molecule Targeted Drug Discovery

Labs

Lab Website

Languages

  • English
  • Hindi

Academic Information

  • Departments: Internal Medicine - Professor, Pharmaceutics and Pharmaceutical Chemistry - Adjunct Professor
  • Divisions: Oncology
  • Cancer Center Programs: Experimental Therapeutics

Board Certification

  • Federal Licensing Examination
  • American Board of Internal Medicine (Sub: Medical Oncology)

Academic Office Information

  • 801-587-5559
  • Huntsman Cancer Institute
    2000 Circle of Hope, Room: 3380
    Salt Lake City, UT 84112

Academic Bio

Sunil Sharma, MD, FACP, MBA

Deputy Director, Huntsman Cancer Institute

Director, HCI Center for Investigational Therapeutics

Professor, Department of Internal Medicine University of Utah

Jon & Karen Huntsman Presidential Professor in Cancer Research

Sunil Sharma, MD, is the Deputy Director of Huntsman Cancer Institute, the Director of the Center for Investigational Therapeutics (CIT), and an investigator at Huntsman Cancer Institute (HCI). Sharma is also a professor in the School of Medicine at the University of Utah and the Co-Leader of the Experimental Therapeutics Program at HCI. He holds a Jon and Karen Huntsman Presidential Professorship in Cancer Research.

Sharma is an expert in the development and testing of new cancer therapies. At HCI, he is working to increase the portfolio of high-quality clinical trials, including phase I trials. He is also establishing a translational oncology lab to support related studies. In addition, his clinical interests are focused on treatment of patients with gastrointestinal cancers (colon, pancreatic, esophageal, rectal, liver), mesothelioma, and rare tumors (carcinoid, neuroendocrine tumors, and carcinomas of unknown primarys).

Before joining HCI, Sharma built a phase I clinical trials program at the Nevada Cancer Institute where he oversaw more than 25 clinical trials. He led a global oncology drug development program at the drug manufacturing company Novartis. He also worked as a physician in the Division of Gastrointestinal Oncology at Memorial Sloan-Kettering Cancer Center, New York City. He earned a medical degree at the University of Delhi, New Delhi, India.

Education History

Type School Degree
Graduate Training University of Massachusetts
Business Administration
M.B.A.
Fellowship University of Texas Health Science Center
Medical Oncology
Fellow
Residency Michael Reese Hospital
Internal Medicine
Resident
Internship Michael Reese Hospital
Internal Medicine
Intern
Residency Post Graduate Institute of Medical Education and Research
Radiology
Junior Resident
Internship University of Delhi Hospital
Rotating Internship
Intern
Professional Medical University of Delhi
Medicine
M.D.
Undergraduate Sardar Patel Vidyalaya
Biology
AISSC

Global Impact

Education History

Type School Degree Country
Residency Post Graduate Institute of Medical Education and Research
Radiology
Junior Resident India
Internship University of Delhi Hospital
Rotating Internship
Intern India
Professional Medical University of Delhi
Medicine
M.D. India
Undergraduate Sardar Patel Vidyalaya
Biology
AISSC India

Career

Institution Description Country
Mantra Bioresearch Founder India

Selected Publications

Journal Article

  1. Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera SZ, Mu S (2015). A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol, 75(1), 87-95.
  2. Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN (2015). Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia, 29(6), 1267-78.
  3. Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA (2014). Colon cancer, version 3.2014. J Natl Compr Canc Netw, 12(7), 1028-59.
  4. Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, Beckerle MC, Sharma S, Lessnick SL (2014). Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res, 20(17), 4584-97.
  5. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN (2014). Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget, 5(14), 5637-50.
  6. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S (2014). Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer, 85(3), 429-34.
  7. Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN (2014). BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther, 13(10), 2315-27.
  8. Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengelov L, Van Veldhuizen P, Agarwala SS, Semiond D, Chadjaa M, Shen L, Wade JL (2014). An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol, 73(6), 1241-52.
  9. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA (2014). Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med, 370(13), 1189-97.
  10. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN (2014). Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia, 28(11), 2155-64.
  11. Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S (2014). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res, 20(2), 480-9.
  12. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, ODay SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ (2014). Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol, 32(2), 129-60.
  13. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN (2014). Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther, 13(5), 1142-54.

Abstract

  1. Wade JL, Dakhil SR, Baron AD, Rottey S, Millard FE, Daugaard G, Machiels J, Conkright WA, Sharma S, Soetekouw P, Yachnin J, Sengelv L, van Veldhuizen P, Agarwala SS, Quyen Nguyen TX, Chadjaa M, Maison-Blanche P (2012). A QTc study of cabazitaxel in patients with advanced solid tumors [Abstract]. Poster ASCO Genitourinary Cancers Symposium.
  2. Shaw AT, Camidge DR, Felip E, Sharma S, Tan DSW, Kim DW, De Pas T, Vansteenkiste JF, Santor A, Liu G, Chow L, Goldwasser M, Lau Y, Boral AL, Mehra R (2012). Results of the first-in-human Phase I study of the ALK inhibitor LDK378 in advanced malignancies [Abstract]. Oral presentation ESMO Congress.

Patent

  1. Vankayalapati H, Sorna V, Warner S, Stephens B, Bearss D, Sharma S (2012). Substituted (E)-N'-(1-Phenylethylidene)Benzohydrazide Analogs as Histone Demethylase Inhibitors”. U.S. Patent No. 8,987,335. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Bearss D, Vankayalapati H, Sorna V, Warner S, Sharma S (2015). “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. 9,206,176. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Bearss D, Vankayalapati H, Sorna V, Warner S, Sharma S (2012). “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.

News

Video